SR9011

REV-ERBα/β Agonism and the Molecular Clock#

SR9011 is a synthetic small-molecule agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2) — heme-binding transcriptional repressors that sit inside the core circadian clock machinery alongside BMAL1/CLOCK/PER/CRY. When SR9011 binds the ligand-binding domain, it stabilizes REV-ERB/NCoR/HDAC3 corepressor complexes on DNA and silences target gene transcription across liver, skeletal muscle, adipose, and immune tissue. That single upstream action is what produces every downstream effect the recomp-focused community cares about.

"SR9009 and SR9011 are potent, selective agonists for REV-ERBα/β and act as transcriptional repressors of clock and metabolic genes, resulting in increased fatty acid oxidation as well as suppressed lipogenesis." — Raza GS et al., International Journal of Molecular Sciences, 2022

Because REV-ERB is itself a clock component, agonism doesn't just nudge metabolism — it reshapes the rhythmic transcription program of whatever tissue is exposed. This is why dose timing matters more here than with virtually any other physique compound.

Skeletal Muscle Mitochondrial Remodelling#

In muscle, REV-ERBα represses genes that normally brake mitochondrial biogenesis. Pharmacological agonism therefore shifts the tissue toward a profile that partially resembles endurance-trained muscle — upregulated fatty-acid oxidation genes, increased mitochondrial content, and in the original Scripps work, improved running capacity in mice.

"Administration of the synthetic REV-ERB agonists SR9009 or SR9011, led to increased energy expenditure in skeletal muscle, decreased fat mass and improved dyslipidemia in mouse models." — Solt LA et al., Nature, 2012

Practically, this is the basis for the conditioning / cardio-tolerance effect users chase. Worth noting: subsequent literature has questioned how much of the Solt phenotype is directly REV-ERB-mediated versus off-target, so the "exercise mimetic" label is better treated as directional than literal.

Hepatic Lipogenesis Suppression and Fat Oxidation#

In liver, REV-ERB agonism represses SREBP-1c, FASN, and ACC — the core lipogenic program — while derepressing fatty-acid oxidation genes in parallel. The net effect in rodent models is reduced hepatic triglyceride synthesis, lower circulating VLDL, and decreased fat mass on a high-fat diet.

This is the mechanistic rationale behind two community use-cases: the cutting/recomp stack (pair with Cardarine's PPARδ-driven fat oxidation for additive signalling) and the speculative on-cycle lipid support idea, where users hope REV-ERB agonism blunts the trig/VLDL blowout from oral AAS. The lipid-support angle is mechanistically plausible but has zero human validation — bloodwork is the only way to know if it's translating in a given protocol.

NLRP3 Suppression and Anti-Inflammatory Signalling#

REV-ERB activation in macrophages suppresses NLRP3 inflammasome assembly and downregulates inflammatory cytokine output.

"Small molecule agonists of REV-ERB, such as SR9011, have demonstrated anti-inflammatory properties through inhibition of NLRP3 signaling in macrophages." — Griffett K., ACS Pharmacology & Translational Science, 2022

For the physique audience this is a double-edged mechanism. On one hand, dampened systemic inflammation is consistent with the subjective "cleaner cardio" and joint-comfort reports from users running it through a prep. On the other, NLRP3 and macrophage signalling are load-bearing parts of normal immune defence, so pharmacological REV-ERB agonism during an active infection is not a situation the preclinical record supports.

Circadian/Sleep Architecture and Why Timing Is Non-Negotiable#

REV-ERBβ is required for normal wakefulness, and SR9011 directly alters sleep-wake behaviour in rodents.

"SR9011 administration significantly increased wakefulness and altered sleep architecture in mice, demonstrating that REV-ERBβ is necessary for these effects." — Amador A et al., Biochemical Pharmacology, 2018

Combined with the compound's pharmacokinetics — poor oral bioavailability, ~2–4 hour plasma half-life in rodents, necessitating frequent dosing (Rivera-Iglesias 2026) — this dictates the protocol shape the community has converged on: three small doses spread across the first half of the waking day, with the final dose landing at least 6 hours before sleep. Evening dosing is the single most reliable way to wreck sleep quality on this molecule, and the mechanism explains exactly why.

Practical Translation#

Every outcome worth chasing on SR9011 — the fat-oxidation tilt, the conditioning effect, the lipogenesis brake, the anti-inflammatory tone — routes through REV-ERB corepressor recruitment at clock-controlled genes. That framing makes three practical consequences obvious:

• Timing beats total dose. A 30 mg/day protocol split 3× in the morning and early afternoon will outperform the same 30 mg dumped at once, both for efficacy (trough exposure between pulses) and for sleep preservation.
• Stack logic follows mechanism. Cardarine (PPARδ) and SR9011 (REV-ERB) act on overlapping but non-identical fat-oxidation programs — hence the canonical recomp pairing. Stacking with a compound that activates inflammatory signalling (e.g. heavy oral AAS blocks) gives REV-ERB agonism a legitimate mechanistic job to do.
• The ceiling is modest. REV-ERB agonism reshapes metabolic tone; it does not build muscle, does not spike strength, and will not substitute for a real caloric deficit. Frame expectations around partitioning and tolerance of a cut, not body-recomposition miracles.

Common (most users)#

• Insomnia / fragmented sleep when dosed too late in the day. SR9011 directly modulates the core clock machinery, and evening exposure reliably pushes sleep onset back. Mitigation: last dose lands ≥6 hours before bed. A typical split is waking / mid-morning / early afternoon.
• Transient fatigue or "flatness" between doses, reflecting the 2–4 hour half-life and the resulting trough periods. Mitigation: tighten the dosing interval to ~4 hours across three doses rather than spreading them across the full waking window.
• Mild appetite shifts — most commonly a blunting of hunger, occasionally a shift in meal timing rather than intake volume. Consistent with rodent data showing altered feeding rhythm rather than a pure anorectic effect. Mitigation: anchor protein and total calories to clock time, not hunger cues, during the cycle.
• GI upset (nausea, loose stools) at the upper end of community dosing. Often a vehicle/solubility issue with oral liquid preparations. Mitigation: dose with a small amount of dietary fat, drop to the next dose tier, and verify product quality via batch COA.

Uncommon (dose-dependent or individual)#

• Lipid panel drift in either direction when stacked with oral AAS. REV-ERB agonism suppresses hepatic lipogenesis in rodents, but the translation to human lipid handling is unproven and variable. Check: full lipid panel + CMP at baseline and 6–8 weeks. Back the stack off if ApoB or trig/HDL ratio moves meaningfully.
• Reduced exercise tolerance paradoxically reported by a minority of users at 30–40 mg/day, likely a circadian-misalignment effect rather than a direct muscular one. Mitigation: drop to 20 mg/day split 3× and re-evaluate after a week.
• Mood flatness / low drive in users sensitive to circadian perturbation. Mitigation: reduce dose and consolidate all administration into the first half of the waking day.
• Dose-wasting at low oral exposure. Not a side effect per se, but relevant — once-daily or twice-daily schedules rarely produce a clean signal given the PK, so users chasing results by raising the total daily dose instead of splitting it more finely are more likely to trigger GI and sleep issues without additional benefit.

"SR9009 and SR9011 display suboptimal pharmacokinetic properties including low oral bioavailability and a short plasma half-life, necessitating frequent administration to maintain effective serum levels in animal models." — Rivera-Iglesias et al., FEBS Letters (2026)

Rare but serious#

• Blunted immune response during active infection. REV-ERB agonism suppresses NLRP3 inflammasome signaling and macrophage inflammatory output — therapeutically interesting, but it means an ongoing cycle during a viral or bacterial infection is working against the host response. Warning signs: prolonged or atypically severe cold/flu course during a cycle. Action: pause administration until resolved.
• Unknown long-term transcriptional consequences. REV-ERB agonists alter expression of hundreds of genes across liver, muscle, adipose, CNS, and immune tissue. No human carcinogenicity, reproductive, or organ-toxicity data exist. This is the defining uncertainty of the molecule and the reason cycles are kept to ≤12 weeks with genuine off-time.
• Counterfeit / mislabeled product. The SR/GW family is among the most frequently faked categories in the research-chemical space. Undosed product is a non-event; overdosed or contaminated product is the actual risk. Mitigation: batch-specific third-party HPLC COA is worth more than brand loyalty.

"Small molecule agonists of REV-ERB, such as SR9011, have demonstrated anti-inflammatory properties through inhibition of NLRP3 signaling in macrophages." — Griffett, ACS Pharmacology & Translational Science (2022)

Hard contraindications#

• Competitive tested athletes. SR9011 and its metabolites are explicitly prohibited at all times under WADA S4.5 (metabolic modulators) and are routinely screened with characterized urinary detection windows. A cycle is a guaranteed positive.

"SR9011 and its metabolites are now routinely targeted in anti-doping screens, and their excretion profiles have been characterized for detection windows in urine." — Gray et al., Drug Testing and Analysis (2025)

• Active infection. The anti-inflammatory / NLRP3-suppressive action works against acute immune response. Cycles pause until the subject is fully recovered.
• Evening dosing. Not a soft guideline — administration in the second half of the waking day reliably degrades sleep architecture and defeats the recomp rationale for running the compound in the first place.
• Pregnancy and lactation. No reproductive or developmental safety data exist. REV-ERB is a core circadian transcription factor with broad tissue expression; pharmacological agonism in this context is not justifiable.

Gender and PCT considerations#

SR9011 is non-hormonal with no HPTA involvement — no testosterone suppression, no estrogenic or androgenic activity, no aromatization. No PCT is required after a cycle. The same dosing framework applies across the subject pool; no sex-specific contraindications have been identified in the preclinical record. Female users running SR9011 as part of a non-hormonal recomp stack (commonly with Cardarine) follow the same 3×/day split and the same 8–12 week ceiling as male users. Baseline and 6–8 week bloodwork (lipid panel + CMP) is the standard monitoring cadence regardless of sex, and becomes more important when SR9011 is layered onto any oral AAS or SARM.